MedTrace Logo

Study to Evaluate Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and COPD Treatment

NCT02384577 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4034

Last updated 2021-11-09

No results posted yet for this study

Summary

The main aim of the study is to investigate patient satisfaction in the treatment of asthma and COPD with the new device of DuoResp® Spiromax® and patient preference. Possible difficulties in the use of the device under real-life conditions in clinical practice are investigated.

Conditions

  • Patient Satisfaction

Interventions

DRUG

Budesonide, Formoterol Fumarate Dihydrate

Sponsors & Collaborators

  • Teva Pharma GmbH

    lead INDUSTRY

Principal Investigators

  • Teva Medical Expert, MD · Teva Branded Pharmaceutical Products R&D, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-03-31
Completion
2016-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02384577 on ClinicalTrials.gov